Novavax submits EUA request to FDA for COVID-19 vaccine
Novavax submitted a request to the U.S Food and Drug Administration (FDA) for emergency use authorization (EUA) for NVX-CoV2373, its protein-based COVID-19 vaccine candidate for the immunization of individuals 18 years of age and older against SARS-CoV-2. Read More
NTx obtains grant to improve mRNA therapy manufacturing, access
NTx has received a grant from the Bill & Melinda Gates Foundation to advance novel solutions for mRNA production and related supply chain challenges. Read More
Sarepta Therapeutics, GenEdit collaborate on gene editing therapies
Sarepta Therapeutics and GenEdit have released results from a research collaboration and option agreement under which the companies are employing GenEdit's NanoGalaxy platform and Sarepta's technology to develop gene editing therapeutics for the treatment of neuromuscular diseases. Read More
Specifica highlights research for its antibody discovery platform
Specifica, a privately held antibody engineering company focused on in vitro antibody library and discovery tools, announced the publication of two peer-reviewed articles describing its Generation 3 Antibody Discovery Platform. Read More
Exopharm, AIRM collaborate on exosome manufacturing
Exopharm has signed a master collaborative services agreement with the Astellas Institute for Regenerative Medicine (AIRM). The agreement entails laboratory work to demonstrate the effectiveness of Exopharm's LEAP, LOAD, and EVPS platforms using AIRM's cell-based therapeutic technologies. Read More
Taysha Gene Therapies reports positive efficacy, safety data for TSHA-120
Taysha Gene Therapies reported positive clinical efficacy and safety data for the high-dose cohort as well as long-term durability data across all therapeutic doses of TSHA-120 in giant axonal neuropathy. Read More
PrecisionLife announces series A financing
PrecisionLife closed its first series A investment round. The financing will enable the expansion and progression of the company's pipeline of commercial opportunities targeting complex chronic diseases. PrecisionLife said it anticipates the second close of the series A investment round in the coming months. Read More
Pfizer, Ionis discontinue vupanorsen
Pfizer and Ionis Pharmaceuticals have discontinued the Pfizer-led clinical development program for vupanorsen, an investigational antisense therapy that was being evaluated for potential indications in cardiovascular risk reduction and severe hypertriglyceridemia. Read More
Human Cell Design launches advanced human beta cell model
Human Cell Design has launched Endoc-BH5, the fifth version of its model of ready-to-use functional human pancreatic beta cells. Read More
I-Mab announces partnership agreement
I-Mab has signed a partnership agreement with the Hangzhou Qiantang New Area in Hangzhou, China, to manufacture the company's drugs and accelerate its transition to commercialization. The strategic partnership will accelerate I-Mab's commercialization strategy with an execution plan and timeline to commercialize its assets, which include felzartamab (TJ202/MOR202), an investigational human monoclonal antibody derived from MorphoSys' HuCal antibody technology. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
